Popular filter options for malaria trials
Malaria Clinical Trials With No Placebo
View 13 malaria medical studies that do not have a placebo group.
Cancer Vaccine
Pvs230D1-EPA/Matrix-M Vaccine for Malaria
This trial will test a new vaccine to stop the spread of malaria. Healthy adults aged 18-50 can volunteer for 3 vaccine visits & 12 clinic visits over 8 months, plus 7 follow-up phone calls over 12 months.
Decision Aid + Standard Care for Malaria
BRIEF SUMMARY Canadians often visit areas with malaria where the preventative drug chloroquine no longer works. This leaves Canadians with the choice to use three different drugs to prevent malaria - atovaquone-proguanil, doxycycline, or mefloquine. There are more than 400 cases of malaria reported in Canada each year, a few which result in death. These cases mainly occur in people who do not take malaria pills as directed. Investigators have developed the Ottawa Malaria Decision Aid (OMDA), which is a bilingual (English and French) resource used to support malaria prevention decision-making. The OMDA contains plain language, fact-based information and helps individuals to reflect on their own values and beliefs so that they can make the best decision for their situation. In this randomized control study, the investigators will attempt to find out if using the OMDA before visiting a travel clinic affects decisional conflict and the way pills are taken. Consenting travellers will be assigned to standard care or standard care plus the malaria decision aid. Both groups will complete three questionnaires before and after travel to look at the impact on decisional conflict, preparation for decision-making, decisional regret and pill taking behaviour. Travelers' malaria can be prevented. It is our hope that by using different methods of presenting information, specifically by utilizing the OMDA, there will be an increase in adherence to appropriate malaria prophylaxis which will ultimately result in a decrease in malaria cases that arrive in Canada. This will translate into a decreased use of health care dollars and unnecessary deaths. The Objectives of this study are to evaluate whether the malaria decision aid can be integrated into the pre-travel consultation process and can: improve a traveller's knowledge of malaria and prevention strategies; improve a traveller's preparation for decision-making; decrease decisional conflict; and affect levels of adherence to prescribed malaria chemoprophylaxis. The hypotheses of this study are that: A decision aid will improve the quality of decision-making about malaria chemoprophylaxis by decreasing decisional conflict and increasing knowledge about malaria and malaria pills. Better decision quality will result in a greater level of adherence to prescribed malaria chemoprophylaxis.
Frequently Asked Questions
Introduction to malaria
What are the top hospitals conducting malaria research?
In the relentless battle against malaria, various hospitals are making important strides in clinical trials to combat this deadly disease. UT Southwestern Medical Center in Dallas has embarked on two active malaria trials, reflecting their commitment to finding innovative solutions for this global health issue. While they have not conducted any malaria trials historically, their current involvement showcases a promising dedication to addressing this pressing challenge.
The National Institutes of Health Clinical Center in Bethesda also plays a significant role in advancing malaria research, with one ongoing trial and a noteworthy record of nine completed trials since delving into this field back in 1998. Their continued efforts demonstrate an unwavering commitment to exploring new treatment options.
Two Baltimore-based institutions are actively contributing to the fight against malaria as well. The Center for Vaccine Development and Global Health located at 685 W. Baltimore Street has initiated one active trial along with one past trial as it began its journey towards understanding and treating malaria starting from 2023.
Similarly, the University of Maryland's Center for Vaccine Development and Global Health is conducting one active trial while having accomplished another previously recorded investigation since commencing its inaugural malaria study in 2022.
Lastly, the Alliance for Multispecialty Research LLC based in Tempe joins these esteemed healthcare providers with their participation in one currently ongoing malaria trial alongside another previous endeavor that was launched together with University of Maryland's CVDGH way back until2022.Their inclusion signifies collaboration among experts across different regions united by a common mission — eradicating the burden of this devastating disease through scientific exploration and innovation.
While progress may vary amongst these institutions due to factors such as location or resources available, each hospital’s contribution is invaluable toward ultimately conquering malaria worldwide. By investing time, expertise, and resources into clinical trials focused on defeating this ancient adversary, researchers pave the way for more effective prevention strategies and life-saving treatments.
Which are the best cities for malaria clinical trials?
When it comes to malaria clinical trials, several cities are at the forefront of research and development. Baltimore, Maryland and Dallas, Texas both have 4 active trials exploring innovative treatments like MAM01, Group 1a: PfSPZ Vaccine, BNT165b1 in Baltimore, and Part A (Phase 2): BIIB059 and Hydroxychloroquine in Dallas. Ottawa, Ontario also contributes to the advancement of malaria treatment with its 3 active trials focused on interventions such as Decision Aid + Standard Care and Part A (Phase 2): BIIB059. While Silver Spring, Maryland and Los Angeles, California each have 2 ongoing studies investigating various approaches including "Low" Dose Treatment and Hydroxychloroquine respectively. These cities provide valuable opportunities for individuals involved in malaria clinical trials as they pave the way for improved prevention and treatment strategies against this deadly disease.
Which are the top treatments for malaria being explored in clinical trials?
Cutting-edge research is leading the charge in finding effective treatments for malaria. MAM01 and BNT165b1 are currently at the forefront of clinical trials, each with one active trial dedicated to combating this deadly disease. Although both treatments are relatively new on the scene, their potential impact cannot be underestimated. MAM01 made its debut in 2023, while BNT165b1 first appeared on the list a year earlier in 2022. As researchers continue to explore these promising options, hope shines brighter for a future where malaria can be effectively treated and controlled.
What are the most recent clinical trials for malaria?
Recent clinical trials have brought new hope in the fight against malaria. One such trial, MAM01, has entered Phase 1 and became available on 8/14/2023. Another Phase 1 trial is Group 1 for malaria, which became available on 8/4/2023. Additionally, BNT165b1 for malaria entered Phase 1 on 12/15/2022. These trials aim to explore innovative approaches to combat this deadly disease and pave the way for potential breakthroughs in treatment and prevention strategies. With ongoing research efforts like these, progress towards eradicating malaria continues to move forward.
What malaria clinical trials were recently completed?
Several significant clinical trials have recently concluded, advancing our understanding and treatment options for malaria. In February 2022, the National Institute of Allergy and Infectious Diseases (NIAID) completed a trial investigating HMPBS02-Pv's efficacy against this devastating disease. Another groundbreaking study was conducted by Sanaria Inc., which successfully finished their PfSPZ Challenge (7G8) trial in September 2021, focusing on controlled human malaria infection (CHMI). Additionally, NIAID completed two important trials in September 2021: VRC-MALMAB0114-00-AB and rCSP. These recent advancements underscore the ongoing efforts to combat malaria through innovative research and provide hope for improved interventions in the future.